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Summary Liposomes containing the photosensitive dye sulphonated aluminium phthalocyanine (AlSPc) were
coupled to polyclonal sheep anti-mouse-Ig antibody and bound to cells coated with specific mouse monoclonal
antibody. When illuminated with red light, the AlSPc in the liposomes was activated to produce singlet oxygen
and the antibody and liposome targeted cells were destroyed. DW-BCL cells (an Epstein Barr virus immorta-
lised B-cell line) were targeted with an anti-B-cell antibody (8A) and killed specifically, both alone and in the
presence of bone marrow mononuclear cells (BM-cells), without phototoxic effects on the untargeted bone
marrow CFU-GM progenitor cells. The presence of an excess of non-target cells did not interfere with
antibody and liposome binding, or light access to target cells. Similar results were obtained with T-
lymphocytes as target cells using anti-CD3 antibody. Specific targeting to the B-cells was demonstrated in the
cell mixtures by use of fluorescent microscopy combined with a sensitive technique to detect low levels of
AlSPc fluorescence, a cooled charge couple device (CCD) camera. This was also able to show low levels of
non-specific background binding of AlSPc to BM-cells and a small population of cells that took up AISPc in
the absence of antibody. The latter were shown to be monocytes by flow cytometry.
In the field of photodynamic therapy, there is a constant
search for more efficient and specific photosensitisers. The
phthalocyanines are a group of compounds which has excited
interest as potentially useful photosensitisers and been much
investigated over recent years (reviewed by Rosenthal, 1991).
There is however, still scope for increasing the specificity of
phthalocyanines for tumour tissue. Liposome incorporation
is one useful possibility (Reddi et al., 1987), and targeting
with antibodies another. It has been previously shown that
liposome encapsulated sulphonated aluminium phthalocya-
nine (AlSPc), is highly phototoxic when targeted to cells by
antibody and activated by light (Morgan et al., 1989). The
phototoxicity of cells is probably due to a Type II photo-
oxidation mechanism in which singlet oxygen is produced by
energy transfer from light activated AlSPc to molecular
oxygen (Sonoda et al., 1987; Agarwal et al., 1990). However,
a contribution to cytotoxicity from a Type I mechanism
cannot be ruled out (Kimel et al., 1989; Ferraudi et al.,
1988). The singlet oxygen mechanism is most likely favoured
over a Type I mechanism in this study because the AlSPc is
in solution inside the liposome, not bound to a target sub-
strate; and under the conditions of treatment there is no
oxygen deprivation. Antibody specificity of the AlSPc lipo-
somes was shown on single cell populations, with non specific
antibodies and cell lines not expressing appropriate antigen
acting as negative controls. The use of such liposomes as an
in vivo therapy may not be effective because of their uptake
in the reticuloendothelial system and limited access to target
cells outside the vasculature. Therefore, it was postulated
(Morgan et al., 1989) that antibody targeted photosensitive
liposomes might be a suitable agent for ex vivo use such as in
the purging of residual tumour from bone marrow for auto-
logous transplantation, and also for treatment for accessible
diseases in anatomical compartments such as bladder carcin-
oma or tumours in the serous cavities. The present paper
demonstrates the feasibility of targeting and destroying
subpopulations of T-lymphocytes and B-cells (using an
immortalised B-cell line as a model) in bone marrow with
photosensitive liposomes without affecting normal bone mar-
row cells.
Materials and methods
Cells
DW-BCL is an in vitro Epstein Barr virus (EBV) immortal-
ised polyclonal B-cell line (Azim, 1988). DW-BCL cells were
seeded at 1 x 105 cells per ml and cultured in RPMI 1640
medium supplemented with 10% foetal calf serum.
Bone marrow was harvested from normal donors, or
patients with non-Hodgkin's lymphoma in remission under-
going harvest for autologous bone marrow transplantation.
Peripheral blood was collected from normal donors. The
mononuclear cells of bone marrow (BM-cells), or peripheral
blood (PBM) were obtained by layering the samples over
Lymphoprep (Nycomed, Norway), centrifuging, and then
collecting and washing the cells at the interface. In some
experiments, the BM-cells were x-irradiated (3000 rad) to
prevent cell division. T-lymphocytes were purified from PBM
by incubating in 20% FCS, in a plastic petri-dish at 37°C for
4 h to allow monocytes to adhere. Non adherent cells were
removed and were found to be greater than 95% positive for
the CD3 antigen (a marker of T-lymphocytes) using UCHTI
antibody and flow cytometry.
Antibodies
8A is an anti-B-cell mouse monoclonal antibody (subclass,
IgGI), directed to an antigen expressed on B-cells from the
pre-B stage of ontogeny through to plasma cells (Tazzari et
al., 1987). It is also expressed on other normal cells including
some T-lymphocytes (personal observations) as well as DW-
BCL cells. 8A was a gift from M. Gobbi and A. Bontadini,
University of Bologna, Italy.
UCHT1 (subclass IgGI), is a mouse monoclonal antibody
against the CD3 cluster antigen expressed on most peripheral
blood T-lymphocytes.
UCHM1 (subclass IgG1), is a mouse monoclonal antibody
against the CD14 antigen expressed on monocytes.
Sheep anti-mouse antibody (SaM), is a polyclonal anti-
body against mouse immunoglobulins produced in a sheep.
This was affinity purified by absorption of the sheep serum
against mouse immunoglobulins and also -against human
immunoglobulins to remove any cross reacting antibodies.
UCHTI, UCHM1 and ScxM were gifts from P. Beverley,
ICRF, Human Tumour Immunology Group, UCL, London.
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Photosensitisers
(i) Tetra-sulphonated AlSPc (tetra-AISPc), prepared by the
condensation method (Weber & Busch, 1965), was a gift
from Russell Svenson, Royal Institution, London, UK.
(ii) TLC-AISPc was a preparation made by the thin layer
chromatographic separation of a mixture of tetra-, tri-, di- an
mono-sulphonated AlSPc (a gift from Ciba-Geigy, Basel,
Switzerland), as described in Morgan et al. (1989). The TLC
preparation was enriched for the more hydrophilic tetra- and
tri-sulphonated derivatives, with residual amounts of the
more lipophilic di- and mono-sulphonated derivatives. HPLC
traces run according to the method of Ambroz et al. (1991)
(Figure 1), show the relative amounts of each component.
Liposomes
Liposomes were small unilamellar vesicles (SUV) with an
average diameter of 50 nm, prepared by ultrasonication.
They were coupled to SaM antibody with N-hydroxysuccini-
midyl 3-(2-pyridyldithio)propionate (SPDP), (Sigma) in the
presence of a buffer containing Hepes (10mM) and NaCl
(145 mM) by the method of Barbet et al. (1981). Lipids used
were La-dipalmitoyl phosphatidylcholine (DPPC) and
cholesterol (both from Sigma), and Lcx-dipalmitoyl
phosphatidylethanolamine-pyridyldithiopropionate in the
ratio 66:33:1. The latter was derived from La-dipalmitoyl
phosphatidylethanolamine (DPPE), (Calbiochem), using
SPDP by the method of Barbet et al. (1981).
For each liposome preparation, 2 x 10-5 moles of SaM
containing a trace of '251I-labelled SaM were used for coupling
to 4 x 10-' moles of total phospholipid. The radioactive
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Figure 1 HPLC traces of: a, unpurified Ciba Geigy preparation
of sulphonated aluminium phthalocyanine and b, TLC purified
preparation of a (TLC-AlSPc), showing the relative proportions
of tetra-, tri-, di, and mono-sulphonated phthalocyanine (respec-
tively 4S, 3S, 2S, lS) present.
trace was included to calculate the amount of antibody
coupled to the liposomes. Tetra-AlSPc or TLC-AlSPc dis-
solved in Hepes buffer (pH 7.4) at 2 mM were encapsulated at
the sonication stage. Control liposomes contained buffer
only. The final concentration of SaM on the liposomes was
1.3 ± 0.2 x 10-6 M (mean ± s.e.m. of nine preparations) and
the lipid concentration measured as DPPC (Stewart, 1980)
was 3.4 ± 0.18 x 10-3M (mean ± s.e.m. of seven prepara-
tions). The liposomes contained on average 47 molecules of
tetra-AlSPc or 49 molecules of TLC-AlSPc. The liposomes
were very stable to storage at 4°C in the dark; and over a
period of 1 month leaked 5-6% of the contents. They were
also stable under the cell treatment conditions, with no
detectable AlSPc leakage after treatment with 7.2 Jcm2 of
light. The liposomes were not washed before use unless they
had been stored for prolonged periods.
Red light source
The light source consisted of two 15 W Grolux fluorescent
tubes (Thorn Lighting Ltd.) fitted with a red gelatin filter,
model 182 (Lee filters Ltd.), as described by Chan et al.
(1986), which gave peak emissions between 600 and 700 nm.
The mean total light intensity (over all the transmitted wave-
lengths) was 2mWcm2 as measured by a Coherent 212
Power meter. Cells were irradiated at 4°C to prevent thermal
effects, the maximum increase of temperature being 40C after
1 h illumination.
Targeting and treatment procedures
Cell targeting
Targeting and phototoxicity of DW-BCL cells alone To
determine the phototoxicity of AlSPc liposomes, DW-BCL
cells were treated with combinations of antibody, liposomes
and light under varying conditions.
For each experimental point, 1 x 104 cells harvested at the
log phase of growth were added to triplicate flat bottomed
wells in 96-well culture plates. They were incubated at 4°C
with 50,l antibody at 2 tgml-' for 30min, and then with
50jsl liposomes for 30min, with three washes in cold serum
free medium between each step.
Antibodies used were 8A (1/1000 dilution of ascites which
contained approximately 2 tgml-' of 8A) or UCHT1 (irre-
levant control), followed by varying liposome dilutions. The
liposomes were prepared with 2 mM tetra-AISPc and different
liposome dilutions were used to give a series of dose response
curves. The lowest dilution of liposomes contained 0.3
nmoles of AlSPc per well (in a total volume of 50 tl) and
doubling dilutions of this were made for the remainder,
containing respectively 0.15, 0.08, and 0.04 nmoles. The
highest AlSPc concentration corresponded to a 6jamolar
dose. Only the highest AlSPc concentration was used with
the irrelevant antibody. Controls were incubated with anti-
body and buffer-only liposomes at similar lipid concentra-
tions as those with AlSPc. Previous studies (unpublished
work) have shown that the absolute number of liposomes in
quantities similar to those used here, had no significant effect
on cell growth; so buffer-only liposomes were only added in
the same proportions as AlSPc-containing liposomes.
Before illumination DW-BCL cells were resuspended in a
volume of 50jil of RPMI medium without- phenol red or
FCS, and then exposed to red light for between 0 and 30 min
to deliver total energies of up to 5.4 Jcm-2 as shown in
Figure 2.
Targeting and phototoxicity of T-lymphocytes Isolated T-
lymphocytes (2 million per treatment point) were incubated
with UCHT1 at 2fgml-', and liposomes and exposed to red
light in the same way as DW-BCL cells. Only one AlSPc
concentration was used, at 0.3 nmoles, and one light dose, of
3.2 J cm-2. Light was given in the absence of phenol red and
FCS. The cells were then suspended at 2 million ml-' and60 J. MORGAN et al.
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Figure 2 Effects of antibody bound tetra-AISPc-liposomes on
DW-BCL cells using an irrelevant antibody UCHTI (Irrel Ab)
and a specific antibody 8A at varying AlSPc-liposome dilutions,
after illumination with red light. Each point is the mean±s.e.m.
of three experiments with triplicates at each point. -0- Irrel
Ab; -A- 0.3 nmoles; -0- 0.15 nmoles; -A 0.08 nmoles;
-*- 0.04 nmoles.
incubated at 37°C until viability was measured by a Trypan
blue exclusion test. Aliquots of the treated cell suspension
were removed at different time periods after treatment, mixed
with an equal volume of 0.2% Trypan Blue solution, and the
number of viable cells, which excluded the dye were counted
in a haemocytometer.
Targeting and phototoxicity of DW-BCL cells or T-lympho-
cytes in a mixedpopulation Theoretically, the presence of an
excess of non-target cells could limit the cytotoxic effect of
liposomes on the target population by reducing either:
(i) Binding of antibody to target cells; or
(ii) The penetration of light to target cells.
This was tested for by the addition of excess non-target
BM-cells. These tests for phototoxicity of mixed populations
could then be compared with those for phototoxicity of
single populations of DW-BCL cells (above). For these
experiments, DW-BCL cells were therefore mixed with a
10-fold excess of BM-cells before targeting with antibody and
liposomes (pre-mixed), and compared with cells mixed after
targeting but before illumination (post-mixed).
For treatment of cell mixtures, x-irradiated BM-cells were
added either before or after the incubation of DW-BCL with
antibody and liposomes, to give a total of 1 x I05 cells per
well (i.e. 10% of the total were DW-BCL). For experiments
in which CFU-GM colonies (colony forming units of macro-
phages and granulocytes) were to be grown to determine
survival of progenitor cells, non-x-irradiated BM-cells were
used in similar proportions (see below).
The quantities of antibodies and liposomes used and the
treatment procedure were similar to those for DW-cell alone,
but only one concentration of tetra-AlSPc liposomes was
used, 0.3 nmoles. In addition, DW-BCL cells in BM-cells
were treated with similar concentrations of TLC-AlSPc lipo-
somes. Cells were resuspended in 50yl of RPMI in the
absence of phenol red or FCS and exposed to varying light
doses of up to 3.6 J cm-2 as shown in Figure 3.
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Figure 3 Specific phototoxicity of 8A antibody bound AlSPc-
liposomes to DW-BCL cells mixed with x-irradiated bone mar-
row mononuclear cells (BM-cells). 'Post-mixed' indicates cells
mixed after targeting but before illumination and 'pre-mixed'
indicates cells mixed before targeting. Also shown are the
phototoxic effects of non-specifically bound liposomes made with
the different preparations of photosensitisers: TLC-AlSPc and
tetra-AISPc (see text), and the effects of light alone on DW-BCL
cells. Each point is the mean±s.e.m. of three experiments with
triplicates at each point. -0- Post-mixed; -A- Pre-mixed;
-0- TLC-AlSPc; -A- Tetra-AlSPc; -*- Light only.
T-lymphocytes already present in BM-cells were also tar-
geted using UCHT1 and liposomes, but in this case, only
CFU-GM colony recovery was assessed and no attempt was
made to determine lymphocyte survival.
Phototoxicity of CFU-GM progenitor cells When the effects
of the AlSPc-liposomes on the 'non-targeted' progenitor cells
were to be examined the BM-cells were not x-irradiated, and
the surviving cells were grown up as CFU-GM colonies. For
these experiments the cells at 7.5 x i0' per well plus 10%
added DW-BCL cells were incubated with antibody and/or
liposomes as shown in Figure 4, and using similar quantities
to previously, then exposed to a total of 0 or 3.6 J cm-2 of
light. Again, 2 mM tetra-AlSPc-liposomes were used at
0.3 nmoles of AlSPc per well, for all samples.
Cellgrowth assays and viability
The DW-BCL cell line is immortalised, but not transformed,
and does not form colonies in soft agar. A tritiated thymi-
dine incorporation assay was therefore used to assess the
phototoxicity of this cell line. Surviving DW-BCL cells were
grown after treatment by incubating in a humidified atmo-
sphere with 5% CO2 at 37@C for 72 h to allow time for the
death of non-viable cells and the regrowth of cells capable of
reproducing. They were pulsed with 3H thymidine (Amer-
sham) at 0.5IACi well for the last 6 h, then harvested onto
filters with an Automash cell harvester (Dynatech). The dried
filters were transferred to vials, scintillation fluid was added,
and the radioactivity in the samples was counted. In the
experiments for examining the effects of photosensitive lipo-
somes on DW-BCL cells in mixtures the BM-cells were x-
irradiated and radioactive counts from controls containing
only x-irradiated BM-cells were subtracted from those con-
taining both DW-BCL cells and BM-cells.PURGING WITH TARGETED PHOTOSENSITIVE LIPOSOMES 61
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Figure 4 CFU-GM recovery from bone marrow mononuclear
cells (BM-cells), alone or mixed with DW-BCL cells and treated
with different mixtures as indicated and either exposed or not
exposed to red light. Columns are means ± s.e.m. of four
experiments using four different bone marrows with triplicate
dishes for each treatment point. , UCHTI only; , 8A
only; , AlSPc-liposomes; , UCHTI + AlSPc-liposomes;
EZI, 8A + AlSPc-liposomes.
For myeloid colony growth, a modification of the method
of Pike and Robinson (1970) was used. DW-BCL/BM-cell
mixtures or pure BM-cells in the case of T-lymphocyte
targeted samples, were added after treatment to soft agar
growth medium in 30 mm petri dishes to give a final number
of 2 x 105 BM-cell per dish in 1 ml of medium. The agar
medium consisted of Iscove's minimum Dulbecco medium
(double strength), foetal calf serum and 0.9% agar dissolved
in double distilled water, in the ratio 3:2.5:3, and contained
10% 5,637 bladder carcinoma cell line conditioned medium
(Fraser et al., 1988) to supply growth factors for colony
growth. The dishes were incubated in a humidified atmo-
sphere in 4% CO2 for 14 days before the CFU-GM colonies
were counted. A colony was scored when it contained more
than 50 cells.
Detection ofspecific targeting to cells
Detection by CCD camera
To show that liposomes only bound to the target populations
of cells, a sensitive technique for detecting small amounts of
fluorescence from light activated AlSPc was used. This was a
cooled charge-coupled device (CCD) camera, as described by
Barr et al. (1988), and was used here with only slight modi-
fications. Briefly, an inverted microscope with epifluorescence
and phase contrast attachments was coupled with a cooled
CCD camera (model 1, resolution 600 x 400 pixels, Wright
Instruments). AlSPc bound to cells was excited with light
from a 1 mW helium-neon laser tuned to 632.8 nm. The laser
beam was focused through the objective and through a glass
slide placed upside down on the stage onto the sample on the
underside of the slide. AlSPc fluorescence between 665 and
700 nm was detected by the CCD camera using suitable band
pass filters and processed by computer to produce a digital
image. The computer also controlled the camera operation.
Photographs of the fluorescent and phase contrast images of
the same field of the slides were recorded from the screen.
Samples for CCD camera examination were prepared as
follows: mixtures of bone marrow and B-cells incubated with
antibody and liposomes were made in the same way as for
the phototoxicity studies above, and fixed in 1% formalde-
hyde solution. Cytospin preparations were then made and the
slides stored at 4°C in the dark until examination.
Flow cytometry
To assess non-specific uptake of liposomes by DW-BCL/BM-
cell mixtures the fluorescence of stained cells was examined
by flow cytometry on a Coulter EPICS flow cytometer set up
to detect red fluorescence from AlSPc and blue fluorescence
from a second layer conjugate bound to monocyte-specific
monoclonal antibody.
Samples of 2 x I05 cells were incubated for 30min with
501sl of liposomes containing 2 mM tetra-AISPc, but with no
SaM attached (to prevent non specific binding of antibodies
in a subsequent incubation with a mouse monoclonal anti-
body). To determine whether cells which took up liposomes
non-specifically in the first incubation were also monocytes,
the cells were incubated with UCHM1 (cell hydridoma cul-
ture medium previously titrated to give optimum binding for
monocytes in PBM), followed by the fluorescent second
layer, Cascade Blue goat anti-mouse immunoglobulin (Mole-
cular Probes, Eugene Oregon). Cells were washed after each
step. Other samples were incubated either with liposomes
only, with UCHM1 and Cascade Blue second layer only, or
with Cascade Blue second layer only, for use as controls and
setting gates on background red and blue fluorescence. Cells
were finally fixed in medium containing 1% formaldehyde
solution and their fluorescence measured.
Fluorescence was excited with uv light at 350 nm and
detected using a 408 nm interference filter to block laser light,
a 550 nm dichroate filter and a 630 nm longpass filter, thus
allowing detecting of blue fluorescence due to Cascade Blue
and red fluorescence due to AlSPc. Ten thousand cells were
assessed on each run, on a linear scale.
Results
Figure 2 shows the phototoxic effect of AlSPc liposomes on
the growth of DW-BCL cell as a percentage of controls as
measured by 3H thymidine uptake. In the presence of light
and a targeting antibody, 3H thymidine uptake by DW-BCL
cells is reduced to less than 1% of controls at the highest
doses of tetra-AISPc and light, whereas in the absence of
targeting antibody, growth was not significantly affected
(student's t-test) at any light dose.
LD50 light doses for the different quantities ofAlSPc added
to cells were 0.73, 1.17, 1.26 and 2.33 Jcm2 for 0.3, 0.15,
0.08 and 0.04nmoles of AlSPc respectively. No LDm was
obtained for non-specific toxicity because it did not reach
such low levels, even at the longest light exposures used.
Typical dose-response curves were obtained for dilutions of
liposomes, showing decreasing growth inhibition for increas-
ing liposome dilutions. This effect could be overcome com-
pletely by increasing the light exposure time for 0.15 nmoles
of AlSPc, but not for the lower doses at the light exposures
used here.
In the presence of x-irradiated BM-cells no significant
difference (student's t-test) was observed between the photo-
toxic killing of DW-BCL cells regardless of whether the
BM-cells were added before or after targeting of the B-cells
with antibody and liposomes, Figure 3. This indicates that
the presence of a 10 fold excess of non-target cells does not
interfere with binding of antibody or light access to the target
cells. In both cases a greater than two log kill was achieved
with an LD50 of 0.7 J cm-2. There was no difference between
tetra-AISPc and TLC-AISPc (data of latter not shown). Some
non-specific toxicity of DW-BCL cells was observed when
UCHT1 was used as an irrelevant antibody for both photo-
sensitiser preparations at higher light doses. For tetra-AISPc-
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at light doses greater than 1.2 Jcm2 (0.005<P<0.01), but
not large enough to give an LDm value. However, when the
TLC-AlSPc-liposomes were used, there was a much greater
non-specific toxicity of DW-BCL cells at light doses of 1.2 J
cm 2 (P 0.0005) and above with an LD,o of 1.24Jcm2.
Non specific toxicity of TLC-AlSPc liposomes were also
significantly greater than that of the tetra-AlSPc at 2.4 J
cm 2 (0.025 <P <0.05) and 3.6 Jcm2 (0.005 <P <0.005).
Table I shows the phototoxicity of T-lymphocytes over a
period of 18 h after targeting and light exposure. Onset of
photokilling is very rapid, with 30% of cells non-viable after
1 h, and very few alive after 18 h. Viability was not counted
over longer periods of time because the untreated control
cells also deteriorated with time.
Figure 4 shows the colony growth of bone marrow samples
expressed as a percentage of untreated controls, after treat-
ment with two different antibodies (8A and UCHT1) and
AlSPc-liposomes in the presence or absence of light. Bone
marrow treated with 8A contained 10% added target DW-
BCL cells, whereas the normal CD3 positive component of
bone marrow was the target for UCHT1. None of these
treatments inhibited CFU-GM growth although they were
effective against target cells (Figure 3, and Table I). There
were no significant differences between any of the treatments,
and no evidence of dark toxicity by AlSPc-liposomes. The
non specific toxicity by AlSPc-liposomes observed for the
DW-BCL cells (above) was not reflected in the recovery of
bone marrow colonies.
Figure 5a shows the digital pattern of fluorescence pro-
duced by exciting AlSPc bound to B-cells cells in bone
marrow by 8A antibody. There is a background population
of faintly stained cells and some brightly fluorescing target
cells. The total number of fluorescent cells was greater than
the 10% of added DW-BCL because of the presence of some
B-lineage cells and some T-lymphocytes (which bind 8A)
among the BM-cells, and non-specific binding and uptake.
Figure 5b shows AlSPc bound to cells non-specifically in the
absence of antibody. The faintly stained background is pres-
ent with the occasional bright cell (arrowed). The latter are
probably due to uptake of liposomes by cells of monocytoid
lineage in the BM-cells or the presence of peripheral blood
macrophages taken up during aspiration of the bone marrow
sample. It was not within the scope of this study to deter-
mine the exact populations of cells in BM-cells that bound
liposomes via 8A antibody, but a brief study of the cells
taking up AlSPc in the absence ofantibody was done by flow
cytometry.
Of the four DW-BCL/BM-cell mixtures examined, the
results gave a range of 4-7% positive for UCHM1, and
6-12% positive for AlSPc above background, which was set
at a level to give 1% positive cells for negative controls. Cells
which were positive for both UCHM1 and AlSPc, corres-
ponded to those of UCHM1 only, in the range 4-7% posi-
tive. Thus the majority of cells exhibiting non-specific uptake
of AlSPc expressed a monocytic phenotype.
Table I Percentage viability of T-lymphocytes (s.e.m. < 10%)
Time - hours after treatment
Treatment 1 2 3 6 18
UCHT1 + AlSPc-liposomes-SaM 70 59 37 12 4
UCHT1 + AISPc-lipsomes 98 97 97 94 92
Untreated 99 99 98 98 97
The table showstheeffectsofantibody-bound tetra-AISPc liposomes
on the viability of isolated peripheral blood T-lymphocytes after red
light illumination. Liposomes containing 2 mM tetra-AISPc were con-
jugated to SaM and bound to T-lymphocytes by UCHTI antibody.
Control tetra-AlSPc liposomes were without SaM.
The viability ofT-lymphocytes, measured by Trypan Blue exclusion,
is expressed as a percentage of the starting number of cells for each
point. Eachfigureisthemeanofthreeexperimentswithduplicatecounts
at each time point. Standard errors of the mean were less than 10%.
b
Figure 5 The photographs show the digital images of AISPc
fluorescence produced by laser excitation of tetra-AISPc in
liposomes, bound specifically to B-cells with anti-B-cell antibody
8A a; and bound or taken up non-specifically in the absence of
targeting antibody b. In both cases, the cells were a mixture of
10% DW-BCL cells in BM-cells.
Discussion
Many patients with haematological malignancies (or solid
tumours) who are either unsuitable for allogeneic bone mar-
row transplantation or do not have HLA-matched donors,
could benefit from the escalation of therapy which is made
possible by an autologous bone marrow transplant (ABMT).
Autologous bone marrow is harvested prior to intensive
therapy following which high dose chemo- or radiotherapy is
given to destroy the tumour. The doses given are also mar-
row ablative. The stored marrow is then reinfused, and after
engraftment haematological function is restored. However,
autologous bone marrow may be contaminated with clono-
genic tumour cells, even though they may be undetectable
morphologically, thereby leading to relapse after ABMT.
To try to prevent this, various methods have been used in
an attempt to purge bone marrow of residual tumour cells.
These include various pharmacological, mechanical and
immunological techniques each of which has its proponents.
An animal model (Sharkis et al., 1980) showed that leu-
kaemic relapse could be prevented by treating bone marrow
with the cytotoxic agent 4-HC (4-hydroperoxycyclophospha-
mide). Another study showed a possible benefit to some
patients with acute non-lymphoblastic and lymphoblastic leu-
kaemia purged with Asta Z 7557, but there was a wide range
of sensitivity to the drug and individual doses were deter-
mined by pre-testing with bone marrow aspirates (Gorin et
al., 1986). A further study showed some evidence of improv-
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leukaemia who received AMBT with grafts purged by 4-HC
(Rowley et al., 1989). More recently, Gorin et al. (1990),
made a multi-centre retrospective analysis of ABMT in
Europe to investigate the benefits of mafosfamide purged vs
non-purged marrow in acute myeloid leukaemia and found a
higher leukaemia-free survival and lower probability of
relapse with purging. There are, therefore, some indications
that purging, even using such non-specific drugs may have a
beneficial effect, although no prospective randomised clinical
trial has demonstrated such a benefit.
The problem with pharmacological agents is their adverse
effect on haemopoietic stem cells as well as tumour stem
cells, which may retard both the onset and extent of haema-
tological reconstitution, an undesirable situation for immuno-
logically compromised patients who have undergone ablative
regimes as part of their therapy. Ideally, more selective
agents would be of benefit, with a greater differential between
tumour kill and stem cell toxicity, resulting in better thera-
peutic index.
Photosensitisers of various types have previously been
shown to have differential toxicity between haemopoietic and
tumour progenitor cells, including merocyanine 540 (Sieber et
al., 1987) which is now being evaluated in phase I clinical
trials, Photofrin II (Atzpodien et al., 1987), and sulphonated
aluminium phthalocyanine (Singer et al., 1988). However, all
of these photosensitisers showed considerably toxicity to
haemopoietic stem cells.
The present study has shown no phototoxicity of CFU-
GM progenitors, combined with high toxicity of targeted
cells which suggests that a targeted method is more selective
in action against tumour cells, with a better therapeutic index
than treatment with free photosensitiser.
Sulphonated aluminium phthalocyanine was chosen for
this investigation because it is available in polar forms which
are hydrophilic and therefore suitable for encapsulating in
liposomes. Tetra-AlSPc liposomes gave low levels of non-
specific toxicity (Figure 3) compared to TLC-AlSPc lipo-
somes which also contained small amounts of the less polar,
lower sulphonated derivatives (as shown in Figure 1). It is
likely that there is the same amount of non-specific adher-
ance to cells for both tetra-AlSPc and TLC-AlSPc liposomes.
However, the tetra-AlSPc, being more highly sulphonated,
and thus more polar than some of the components in TLC-
AlSPc, is relatively less able to cross the lipid bilayer of the
lipsome and pass into the cell membrane, thus producing less
toxicity. Greater non specific toxicity was noted in the DW-
BCL/BM-cell mixtures than when the DW-BCL cells alone
were targeted. This may be due to the presence of AlSPc
bound non-specifically to the large excess of BM-cells. Simi-
lar LD50 results were obtained for both specific DW-BCL cell
toxicity in marrow (0.70 Jcm2) and DW-BCL cells alone
(0.73 J cm-2) using 0.3 nmoles of AlSPc. Previous results
obtained for the same dose of AlSPc on DW-BCL when
illuminated in the presence of growth medium (RPMI with
phenol red and 10% FCS) gave an LD50 of 0.9 J cm2, an
increase of 23% (results not shown). A further series of eight
experiments comparing phototoxicity of DW-BCL treated
with 0.3 nmoles of AlSPc and 3.6 J cm-2 of light in the
presence and absence of growth medium, showed a mean
increase of cell survival of 27.5 ± 6.9% in the former case. It
is obviously of great importance that interfering substances
are minimised during the light activation stage. Both phenol
red and FCS interfere slightly with light penetration by absor-
bing light. At the main absorption peak of AlSPc (675 nm)
which is also one of the main emission peaks of the light
source, absorbance due to phenol red and FCS amounts to
1.1%, with the phenol red contribution being 0.4%. This is
not sufficient to account for the difference in cellular photo-
toxicity obtained in the presence and absence of these agents.
Human plasma (Kanofsky, 1990), and FCS (Parker & Stan-
bro, 1984), have been shown to quench singlet oxygen. The
presence of FCS in the medium would therefore be expected
to inhibit the action of the singlet oxygen produced, and
protect against its toxicity. It is unlikely that the effects of
serum were due to any direct interaction with AlSPc, since it
is protected from the external medium by the lipid bilayer.
It is interesting that no toxicity occurred to CFU-GM
progenitors, despite the presence of low levels of non-speci-
fically bound AlSPc as shown in Figure 5. This may be due
to a lower susceptibility of progenitors to oxidative damage.
Seven day CFU-GM colonies which represent a later, more
committed progenitor were not counted because the clusters
and colonies were too numerous, which indicates that it is
not just the earlier progenitors that were protected. This
contrasts with another study also using 8A antibody to target
cells (Dinota et al., 1990), but using free radicals produced by
the enzyme activity of xanthine oxidase on a substrate in the
medium, in which 7 days, but not 14 days CFU-GM were
affected, though their results were otherwise similar to ours.
The antibody targeted liposome system as described here
for destroying specifically targeted cells in bone marrow bone
appears to have many advantages as a bone marrow purging
agent. AlSPc is not toxic until it is activated by red light, and
then the onset of photodamage is very rapid as indicated by
the decrease in viability of T lymphocytes in Table I. Large
quantities of photosensitiser may be encapsulated in the lipo-
somes and an additional amplification occurs during irradia-
tion because each photosensitiser molecule is 'reusable' and
can be activated several times over, producing large amounts
of the toxic species single oxygen for relatively small
quantities of AlSPc. Furthermore the toxic reactions is not
dependent on cells being in an active phase of cycling, as
demonstrated by the antibody targeted phototoxicity of un-
stimulated T-lymphocytes. This means that clonogenic cells
in Go can be targeted and destroyed. The T-lymphocytes in
this study were obtained from 'non-responders'. These are
donors whose T-lymphocytes are not activated via the CD3
pathway in response to the binding of anti-CD3 antibodies,
in this case of subclass IgGI (Smith et al., 1986), thus
ensuring that the lymphocytes were quiescent during treat-
ment.
The use of a polyclonal antibody on the liposomes means
that several mouse monoclonal antibodies can be used
together as a cocktail with the same AlSPc preparation. Also,
because the AlSPc containing liposomes need not be inter-
nalised to be toxic (Morgan et al., 1989), since the singlet
oxygen produced is able to diffuse towards the cell, many cell
surface antigens that would not normally be internalised can
be used to extend the number of potential binding sites on
the target cells. A combination of antibodies against both
endocytosing and non-endocytosing antigens might be the
best option to use, to attack the cell from both the inside and
the outside.
We would like to thank Bloomsbury Health Authority for the grant
that supported this work. Grateful thanks are also due to Arnold
Pizzey who set up and ran the EPICS for the flow cytometry.
References
AGARWAL, R., ATHAR, M., BICKERS, D.R. & MUKHTAR, H. (1990).
Evidence for the involvement of singlet oxygen in the photodes-
truction by chloroaluminium phthalocyanine tetrasulphonate.
Biochem. Biophys. Res. Comm., 173, 34.
AMBROZ, M., BEEBY, A., MAcROBERT, A.J., SIMPSON, M.S.C., SVEN-
SON, R.K. & PHILLIPS, D. (1991). Preparative, analytical and
fluorescence spectroscopic studies of sulphonated aluminium
phthalocyanine photosensitisers. J. Photochem. Photobiol. B:
Biol., 9, 87.
ATZPODIEN, J., GULATI, S.C., STRIFE, A. & CLARKSON, B.D. (1987).
Photoradiation models for the clinical ex vivo treatment of auto-
logous bone marrow grafts. Blood, 70, 484.
AZIM, T. (1988). PhD Thesis, University of London.
BARBET, J., MACHY, P. & LESERMAN, L.D. (1981). Monoclonal
antibody covalently coupled to liposomes: specific targeting to
cells. J. Supramol. Struct. Cell Bioch., 16, 237.64 J. MORGAN et al.
BARR, H., TRALAU, C.J., MACROBERT, A.J., MORRISON, I., PHIL-
LIPS, D. & BOWN, S.G. (1988). Fluorescence photometric techni-
ques for determination of microscopic tissue distribution of
phthalocyanine photosensitisers for photodynamic therapy.
Lasers Med. Sci., 3, 81.
CHAN, W.S., SVENSON, R., PHILLIPS, D. & HART, I.R. (1986). Cell
uptake, distribution and response to aluminium chloro sulpho-
nated phthalocyanine, a potential antitumour photosensitiser. Br.
J. Cancer, 53, 255.
DINOTA, A., TAZZARI, P.L., ABBONDANZA, A., BATTELLI, M.G.,
GOBBI, M. & STIRPE, F. (1990). Bone marrow purging by a
xanthine oxidase-antibody conjugate. Bone Marrow Transplant, 5,
31.
FERRAUDI, G., ARGUELLO, G.A., ALI, H. & VAN LIER, J.E. (1988).
Types I and II sensitised photooxidation of aminoacid by phtha-
locyanines: a flash photochemical study. Photochem. Photobiol.,
47, 657.
FRASER, J.K., LIN, F. & BERRIDGE, M.V. (1988). Expression and
modulation of specific high affinity binding sites for erythro-
poietin on the human erythroleukaemic cell line K562. Blood, 71,
104.
GORIN, N.C., DOUAY, L., LAPORTE, J.P. & 15 others (1986). Auto-
logous bone marrow transplantation using marrow incubated
with Asta Z 7557 in adult acute leukaemia. Blood, 67, 1367.
GORIN, N.C., AEGERTER, P., AUVERT, B. & 19 others (1990). Auto-
logous transplantation for acute myelocytic leukaemia in first
remission: a European survey of the role of marrow purging.
Blood, 75, 1606.
KANOFSKY, J.R. (1990). Quenching of singlet oxygen by human
plasma. Photochem. Photobiol., 51, 299.
KIMEL, S., TROMBERG, B.J., ROBERTS, W.G. & BERNS, M.W. (1989).
Singlet oxygen generation of porphyrins, chlorins and phtha-
locyanines. Photochem. Photobiol., 50, 175.
MORGAN, J., GRAY, A.G. & HUEHNS, E.R. (1989). Specific targeting
and toxicity of sulphonated aluminium phthalocyanine photosen-
sitised liposomes directed to cells by monoclonal antibody in
vitro. Br. J. Cancer, 59, 366.
PIKE, B.L. & ROBINSON, W.A. (1970). Human bone marrow colony
growth in agar-gel. J. Cell. Physiol., 76, 77.
PARKER, J.G. & STANBRO, W.D. (1984). Dependence of photosen-
sitised singlet oxygen production on porphyrin structure and
solvent. In: Porphyrin localisation and treatment of tumours,
Doiron, D.R. & Gomer, C.J. (eds), p. 259. Alan R. Liss Inc.,
New York.
REDDI, E., CASTRO, G.L., BIOLO, R. & JORI, G. (1987). Pharmaco-
kinetic studies with zinc(II)-phthalocyanine in tumour-bearing
mice. Br. J. Cancer, 56, 597.
ROSENTHAL, I. (1991). Phthalocyanines as photodynamic sensitizers.
Photochem. Photobiol., 53, 859.
ROWLEY, S.D., JONES, R.J., PIANTADOSI, S. & 8 others (1989).
Efficacy of ex vivo purging for autologous bone marrow trans-
plantation in the treatment of acute nonlymphoblastic leukaemia.
Blood, 74, 501.
SHARKIS, S.J., SANTOS, G.W. & COLVIN, M. (1980). Elimination of
acute myelogenous leukaemic cells from marrow and tumour
suspensions in the rat with 4-hydroperoxycyclosphophamide.
Blood, 55, 521.
SIEBER, F. (1987). Marrow purging by merocyanine 540-mediated
photolysis. Bone Marrow Transplant, 2, (Suppl 2) 29.
SINGER, C.R.J., LINCH, D.C., BOWN, S.G., HUEHNS, E.R. & GOLD-
STONE, A.H. (1988). Differential phthalocyanine photosensitisa-
tion of acute myeloblastic leukaemia progenitor cells: a potential
purging technique for autologous bone marrow transplantation.
Br. J. Haematol., 68, 417.
SMITH, K., AUSTIN, J.M., HARIRI, G., BEVERLEY, P.C.L. & MORRIS,
P.J. (1986). T-cell activation by anti-T3 antibodies: comparison of
IgG 1 and IgG2b switch variants and direct evidence for acces-
sory function of macrophage Fc receptors. Eur. J. Immunol., 16,
478.
SONODA, M., MURALI KRISHNA, C. & RIESZ, P. (1987). The role of
singlet oxygen in the photohemolysis of red blood cells sensitised
by phthalocyanine sulphonates. Photochem. Photobiol., 46, 625.
STEWART, J.C.M. (1980). Colorimetric determination of phospho-
lipids with ammonium ferrothiocyanate. Anal. Biochem., 104, 10.
TAZZARI, P.L., GOBBI, M., DINOTA, A. & 7 others (1987). Normal
and neoplastic plasma cell membrane phenotype. Studies with
new monoclonal antibodies. Clin. Exp. Immunol., 70, 192.
WEBER, J.H. & BUSCH, D.H. (1965). Complexes derived from strong
field ligands. XIX. Magnetic properties of transition metal deriva-
tives of 4,4',4",4"'-tetrasulphophthalocyanine. Inorg. Chem., 4,
469.